Skip to main content

Table 5 Acute and late toxicities in the propensity-matched cohorts [n (%)]

From: Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas

Toxicities

P67.5

P70

P*

Grade 0

Grade 1-2

Grade 3-4

Grade 0

Grade 1-2

Grade 3-4

Acute toxicities

       

 Skin reaction

5 (3.4%)

137 (92.5%)

6 (4.1%)

5 (3.4%)

136 (91.9%)

7 (4.7%)

0.961

 Mucositis

2 (1.4%)

133 (89.8%)

13 (8.8%)

1 (0.7%)

141 (95.2%)

6 (4.1%)

0.207

 Xerostomia

2 (1.4%)

146 (98.6%)

0

7 (4.7%)

141 (95.3%)

0

0.091

 Pharyngo-esophagitis

0

144 (97.3%)

4 (2.7%)

4 (2.7%)

143 (96.6%)

1 (0.7%)

0.055

 Leucopenia

31 (20.9%)

79 (53.4%)

38 (25.7%)

58 (39.2%)

80 (54.0%)

10 (6.8%)

0.000

 Anemia

73 (49.3%)

71 (48.0%)

4 (2.7%)

137 (92.6%)

11 (7.4%)

0

0.000

 Thrombocytopenia

118 (79.7%)

23 (15.6%)

7 (4.7%)

140 (94.6%)

8 (5.4%)

0

0.000

 Weight loss

<5%

13 (8.8%)

5%-10%

39 (26.3%)

≥10%

96 (64.9%)

<5%

16 (10.8%)

5%-10%

47 (31.7%)

≥10%

85 (57.5%)

0.423

Late toxicities

Grade 0

Grade 1

Grade 2+

Grade 0

Grade 1

Grade 2+

 

 Subcutaneous fibrosis

92 (62.2%)

53 (35.8%)

3 (2.0%)

87 (58.8%)

51 (34.5%)

10 (6.7%)

0.139

 Xerostomia

29 (19.6%)

111 (75.0%)

8 (5.4%)

19 (12.8%)

122 (82.4%)

7 (4.7%)

0.263

 Otitis media

116 (78.4%)

32 (21.6%)

0

116 (78.4%)

31 (20.9%)

1 (0.7%)

0.602

 Taste changes

106 (71.6%)

41 (27.7%)

1 (0.7%)

120 (81.1%)

25 (16.9%)

3 (2.0%)

0.057

 Dehisce difficulty

122 (82.4%)

25 (16.9%)

1 (0.7%)

132 (89.2%)

16 (10.8%)

1 (0.7%)

0.306

 Hearing loss

75 (50.7%)

60 (40.5%)

13 (8.8%)

80 (54.1%)

59 (39.9%)

9 (6.1%)

0.639

 Tooth and periodontal diseases

86 (58.1%)

56 (37.8%)

6 (4.1%)

80 (54.1%)

52 (35.1%)

16 (10.8%)

0.086

 Hypothyroidism

143 (96.6%)

4 (2.7%)

1 (0.7%)

138 (93.2%)

8 (5.4%)

2 (1.4%)

0.416

  1. *P-values were calculated using the Pearson χ2 test